---
tags:
  - gp_training
---
## 1. Big picture: what NICE actually produces
NICE doesnâ€™t make â€œone typeâ€ of guidance. It produces **different products for different jobs**:
- **Clinical practice** (what to do)
- **Funding decisions** (what the NHS must pay for)
- **Quality measurement** (what good care looks like)
- **Public health & prevention**
- **Local commissioning support**

Thatâ€™s why you keep seeing **NG**, **TA**, **QS**, **Indicators**, etc.

---
## 2. Core NICE products (the ones you must know)
### ğŸ”µ 1. NICE Guidelines (**NG**)
**Example:** NG203 â€“ Chronic kidney disease
**What they are**
- Broad **clinical practice guidelines**
- Cover **diagnosis, monitoring, referral, management**
- Evidence-based, consensus-driven

**What they do NOT do well**
- They often **donâ€™t give drug-by-drug eligibility**
- They may say _â€œconsider drug Xâ€_ without thresholds

**Status**
- Advisory but **very influential**
- Courts, CQC, examiners treat them as gold standard

**Use them when**
- Writing management plans
- Answering exams
- Structuring GP care

---
### ğŸŸ£ 2. NICE Technology Appraisals (**TA**)
**Examples:**
- TA775 â€“ Dapagliflozin for CKD
- TA942 â€“ Empagliflozin for CKD

**What they are**
- **Legal funding decisions**
- Decide whether the NHS **must provide a drug**
- Very specific inclusion/exclusion criteria

**Key point**
> If a drug has a positive TA, the NHS is **legally obliged** to fund it (within criteria)

**Why CKD SGLT2i live here**
- Because they are **new, expensive drugs**
- NG203 refers you _out_ to TAs for details

**Use them when**
- Starting expensive meds
- Challenging an ICB
- Being precise about eligibility

ğŸ“Œ **If NG says â€œconsiderâ€ but TA says â€œrecommendedâ€ â†’ TA wins for access**

---
### ğŸŸ¢ 3. NICE Quality Standards (**QS**)
**Example:** QS5 â€“ CKD quality standard
**What they are**
- Short statements of **what high-quality care looks like**
- Each QS has:
    - A statement
    - A rationale
    - A measurable outcome

**Example**
> â€œPeople with CKD and ACR â‰¥3 are offered ACE inhibitors.â€

**They are NOT**
- Full guidelines
- Not detailed management plans

**Use them when**
- Audits
- QOF-style thinking
- Explaining â€œstandard of careâ€

---
### ğŸŸ  4. NICE Quality Indicators
**Example:** IND322 â€“ CKD and SGLT2 inhibitors
**What they are**
- **Measurable metrics** derived from QS/TAs
- Used for:
    - Population health
    - Benchmarking
    - Service evaluation

**Important nuance**
- They often **operationalise** TAs
- Thatâ€™s why they give **clear eGFR + ACR cut-offs**

**Why they matter clinically**
- They reveal what NICE _expects_ to be happening in practice
- They often feel more â€œpracticalâ€ than NGs

ğŸ“Œ For CKD + SGLT2i, **IND322 is the clearest NICE document** for non-diabetics.

---
## 3. Other NICE products (know them, donâ€™t memorise)
### ğŸŸ¡ Public Health Guidelines (**PH**)
Now NG
- Prevention, screening, lifestyle
- e.g. smoking, obesity, physical activity
### âš« Interventional Procedures Guidance (**IPG**)
- Safety/efficacy of procedures
- Not about funding
- e.g. new surgical techniques
### ğŸ”´ Medical Technologies Guidance (**MTG**)
- Devices, diagnostics
- e.g. monitoring tech
### ğŸ”µ Diagnostics Guidance (**DG**)
- Cost-effectiveness of diagnostic tests

---
## 4. One-table summary (bookmark this mentally)

|Type|Code|Purpose|Binding?|Example|
|---|---|---|---|---|
|Guideline|NG|Clinical practice|Advisory (strong)|NG203 CKD|
|Technology Appraisal|TA|Drug funding|**Legally binding**|TA775 dapagliflozin|
|Quality Standard|QS|Defines good care|Advisory|QS5 CKD|
|Indicator|IND|Measures care delivery|Monitoring|IND322 SGLT2i in CKD|
|Public Health|PH|Prevention|Advisory|PH smoking|
|Interventional|IPG|Procedures safety|Advisory|IPG surgery|

---
## 5. How _you_ should use these in practice (GP lens)
- **Exams / teaching** â†’ **NG**
- **Starting new expensive drugs** â†’ **TA**
- **Audits / QOF / ARRS logic** â†’ **QS + Indicators**
- **â€œWhy is the ICB asking for this?â€** â†’ **Indicators**
- **Disputes about funding** â†’ **TA (always wins)**

---
## 6. CKD + SGLT2i example (pulling it together)
- NG203 â†’ says SGLT2i are part of CKD management    
- TA775 / TA942 â†’ legally approve use in **non-diabetic CKD**
- IND322 â†’ tells services **exactly which patients** should be on them

Thatâ€™s why **the detail lives outside the NG**.
